abstract |
The present invention relates generally to the generation and characterization of neutralizing anti-IFN-a monoclonal antibodies with broad reactivity against various IFN-a subtypes. The invention further relates to the use of such anti-lFN-aX antibodies in the 5 diagnosis and treatment of disorders associated with increased expression of IFN-ca, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). 2570171_1 (GHMAIcr) 18-F, 11 CY) en. , LLL IL IL IL Z ___ __L ___ __ ____L_ ___-L___ ___ _ U)V c -0 z Nv LLA13 U-aJ~ |